Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BSJ-4-116 is a highly potent and selective CDK12 degrader (PROTAC) with an IC50 of 6 nM. It downregulates DDR genes through a premature termination of transcription, primarily through increasing poly(adenylation).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 62.00 | |
5 mg | In stock | $ 133.00 | |
10 mg | In stock | $ 226.00 | |
25 mg | In stock | $ 490.00 | |
50 mg | In stock | $ 723.00 | |
100 mg | In stock | $ 987.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 198.00 |
Description | BSJ-4-116 is a highly potent and selective CDK12 degrader (PROTAC) with an IC50 of 6 nM. It downregulates DDR genes through a premature termination of transcription, primarily through increasing poly(adenylation). |
Targets&IC50 | CDK12:6 nM |
In vitro | BSJ-4-116 (50?nM; 6-24?hours) decreases the level of CDK12 protein, regardless of the mutational status of the cell line.BSJ-4-116 (10-10000 nM; 72 hours) exhibits potent antiproliferative effects in Kelly CDK12C1039F.BSJ-4-116 inhibits the growth of T-ALL cells (Jurkat and MOLT-4 cells) and sensitizes them to PARP inhibition. BSJ-4-116 regulates DDR genes via poly(adenylation). BSJ-4-116 overcomes CDK12C1039F mutation. BSJ-4-116 represents the first example of resistance to a bivalent degrader molecule that is a consequence of an acquired point mutation in the target protein. |
Molecular Weight | 837.38 |
Formula | C40H49ClN8O8S |
CAS No. | 2519823-34-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (298.55 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BSJ-4-116 2519823-34-6 Cell Cycle/Checkpoint PROTAC Ligand for E3 Ligase CDK degrader antiproliferative inhibit Kelly C1039F BSJ 4 116 Cyclin dependent kinase PROTACs cancer Inhibitor CDK12 mutation BSJ4116 inhibitor